Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.
Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.
Immunovaccine showed that its cancer vaccine, when paired with Incyte's epacadostat, might work in ovarian cancer.
Here's some other vaccine news of note for the week.
On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.
Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.
With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.
Before heading offshore for a dubious herpes vaccine trial, a Southern Illinois University did such experiments on people in the U.S.
Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.
Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.